Mutation to inherited HSD3B1 gene associated with more aggressive form of prostate cancer

According to an article to appear in the September issue of The Lancet Oncology, some patients with aggressive prostate cancer are more likely to die earlier from their disease if they carry a specific testosterone-related genetic abnormality. … READ MORE …

Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

PCA3, mpMRI, targeted biopsies, and risk for diagnosis of prostate cancer

The degree to which the PCA3 test is a useful tool in assessment of risk for clinically significant prostate cancer prior to biopsy has never, really, been entirely clear. … READ MORE …

Probability of remaining recurrence-free after salvage radiation

Nearly 10 years ago, in 2007, Stephenson et al. published a nomogram that predicted the probability of success of salvage radiation therapy (SRT) after post-prostatectomy biochemical failure. … READ MORE …

Obesity and risk for diagnosis with prostate cancer

A new report from the International Agency Research on Cancer (IARC) Handbook Working Group has concluded that there is a definitive link between “body fatness”  and increased risk for diagnosis with 13 different types of cancer — but prostate cancer is not on that list. … READ MORE …

Of zinc ions, MRIs, and those ubiquitous research mice again

According to a story issued by the media staff for the University of Texas Southwestern Medical Center, a novel form of MRI technique may be able to distinguish between healthy prostate tissue and cancerous prostate tissue — based on zinc levels in the tissues. … READ MORE …

Pfizer to buy Medivation (developer of Xtandi)

According to news this morning, Pfizer has entered into a merger agreement which will allow the company to buy Medivation (the developer of enzalutamide, also known as Xtandi). Rumors had been rife since last Friday. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,455 other followers